Macrolide antibiotic. Inhibits protein synthesis (elongation) at the transpeptidation step. Binds to the 23S RNA of the 50S ribosomal subunit. Effective against Gram-negative and Gram-positive bacteria.
Product Details
Formula: | C37H67NO13 |
|
MW: | 733.9 |
|
Source: | Isolated from Streptomyces erythreus. |
|
CAS: | 114-07-8 |
|
MI: | 14: 3681 |
|
RTECS: | KF4375000 |
|
Purity: | ≥85% (Assay on dry basis) |
|
Appearance: | White to off-white powder. |
|
Solubility: | Soluble in water (50mg/ml), 100% ethanol or methanol. |
|
Shipping: | Ambient Temperature |
|
Long Term Storage: | -20°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism: T. Tokairin, et al.; Br. J. Clin. Pharmacol.
60, 172 (2005),
Abstract;
Full Text
Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban: J.Q. Tran, et al.; J. Clin. Pharmacol.
39, 513 (1999),
Abstract;
Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells: Y. Aoki & P.N. Kao; Antimicrob. Agents Chemother.
43, 2678 (1999),
Abstract;
Full Text
Inducible erythromycin resistance in bacteria: B. Weisblum; Br. Med. Bull.
40, 47 (1984),
Abstract;
Related Products